AXSMStock
Verdicts genuinely change. Free email alert the moment AXSM's does — no target price to set, unlike a price alert.
Stable Ratio screen, 4 of 4 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it
Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Trade setup
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Trade plan
Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.
Why this signal?
The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.
AXSM is currently considered halal (Sharia-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.
This sits among 434 compliant Healthcare stocks we track. See compliant Healthcare stocks →
How the status reached this point
Compliant · status tracked since Nov 17, 2026
No change to AXSM’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.
Read once a day from our own screen, last on Nov 17, 2026. The per-methodology record is under “What changed, and when” in the in-house research.
🕌 In-house Compliance Research
Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.
AAOIFI divides by the market cap: $7.2B as of 2026-11-16. At the 2026-11-18 close it is about $6.9B (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 3.0% (2.9% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 4.5% (4.3% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.
Business activity: cleared (no excluded categories detected)
AAOIFI Pass 3 of 3 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 2.89% | 30.00% | Pass(27.1pp buffer) |
| Interest-bearing investments | 4.33% | 30.00% | Pass(25.7pp buffer) |
| Non-permissible income | 1.47% | 5.00% | Pass(3.5pp buffer) |
Usmani Unverified⚠️ implied interest rate too low — debt may be double-counted 3 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 27.12% | 33.00% | Pass(5.9pp buffer) |
| Interest-bearing investments | 37.96% | 33.00% | Fail(5.0pp over) |
| Non-liquid assets | 20.54% | at least 20.00% | Pass(0.5pp above the floor) |
| Non-permissible income | 1.47% | 5.00% | Pass(3.5pp buffer) |
MSCI Unverified⚠️ implied interest rate too low — debt may be double-counted 2 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 25.34% | 33.33% | Pass(8.0pp buffer) |
| Cash + interest-bearing securities | 37.96% | 33.33% | Fail(4.6pp over) |
| Accounts receivable | 79.46% | 33.33% | Fail(46.1pp over) |
| Non-permissible income | 1.47% | 5.00% | Pass(3.5pp buffer) |
FTSE Unverified⚠️ implied interest rate too low — debt may be double-counted 2 of 4 ratios pass
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 22.75% | 33.33% | Pass(10.6pp buffer) |
| Cash + interest-bearing securities | 37.96% | 33.33% | Fail(4.6pp over) |
| Accounts receivable | 79.46% | 50.00% | Fail(29.5pp over) |
| Non-permissible income | 1.47% | 5.00% | Pass(3.5pp buffer) |
Dow Jones Islamic Market Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 2.63% | 33.00% | Pass(30.4pp buffer) |
| Cash + interest-bearing securities | 3.94% | 33.00% | Pass(29.1pp buffer) |
| Accounts receivable | 4.31% | 33.00% | Pass(28.7pp buffer) |
| Non-permissible income | 1.47% | 5.00% | Pass(3.5pp buffer) |
S&P Shariah Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 3.15% | 33.00% | Pass(29.9pp buffer) |
| Cash + interest-bearing securities | 4.71% | 49.00% | Pass(44.3pp buffer) |
| Accounts receivable | 5.15% | 49.00% | Pass(43.8pp buffer) |
| Non-permissible income | 1.47% | 5.00% | Pass(3.5pp buffer) |
MSCI M-Series Pass 4 of 4 ratios pass
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 3.15% | 33.33% | Pass(30.2pp buffer) |
| Cash + interest-bearing securities | 4.71% | 33.33% | Pass(28.6pp buffer) |
| Accounts receivable | 9.87% | 49.00% | Pass(39.1pp buffer) |
| Non-permissible income | 1.47% | 5.00% | Pass(3.5pp buffer) |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
How close is it to flipping?
Every current reading against its own line, closest first. A verdict is only as durable as that distance.
The numbers the ratios are built from
Read from AXSM's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $638.5M | 2025-12-31 | RevenueFromContractWithCustomerExcludingAssessedTax |
| Interest-bearing debtShort and long-term borrowings | $188.1M | 2026-09-30 | LongTermDebtNoncurrent, LongTermDebtCurrent |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $313.9M | 2026-09-30 | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
| Total assetsBalance sheet total | $826.8M | 2026-09-30 | Assets |
| Market capDenominator for AAOIFI | $7.2B | live quote | price x shares |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | $6.4B | 756 trading days | closes x shares |
| 24-month average market capDenominator for Dow Jones Islamic Market | $7.6B | 504 trading days | closes x shares |
| Non-permissible revenueInterest and excluded income | $9.4M | 2025-12-31 | InterestIncomeOperating |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Sources
Filing information. Balance sheet as of 2026-09-30. Income statement as of 2025-12-31. Screened 2026-11-16.
Filing links appear after the next screen: this row was screened before filing citations were recorded.
-
Total assets$826.8M
Assets· balance sheet as of 2026-09-30 -
Interest-bearing debt$188.1M
LongTermDebtNoncurrent, LongTermDebtCurrent· balance sheet as of 2026-09-30 -
Cash and interest-bearing securities$313.9M
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents· balance sheet as of 2026-09-30 -
Receivables$343.1M
AccountsReceivableNetCurrent· balance sheet as of 2026-09-30 -
Revenue$638.5M
RevenueFromContractWithCustomerExcludingAssessedTax· income statement as of 2025-12-31 -
Interest income (non-permissible)$9.4M
InterestIncomeOperating· income statement as of 2025-12-31 -
Market cap$7.2BMarket-data quote at screen time, 2026-11-16 · not a filing figure, so no link
What changed, and when
Verdict history for AXSM. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
- 2026-09-07 No change recorded No verdict change for AXSM has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.
Tracked since 2026-09-07.
What would change the status
The headline verdict is the majority of the decided ratio standards — 4 pass and 0 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-16.
No standard's deciding ratio sits within 3 points of its line.
The ratios that move with the share price
AAOIFI's debt ratio (2.9% against a 30% line) would only fail if the market cap fell by 90%, to $698.3M. At the 2026-11-18 close it would read 3.0%.
AAOIFI's investments ratio (4.3% against a 30% line) would only fail if the market cap fell by 86%, to $1.0B. At the 2026-11-18 close it would read 4.5%.
Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.
Shariah-compliant alternatives
Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.
| Company | Market cap | Price, day |
|---|---|---|
| VRTXVertex Pharmaceuticals, Inc. | $121.1B | — |
| REGNRegeneron Pharmaceuticals, Inc. | $85.3B | — |
| ARGXArgen X SE - ADR | $64.3B | — |
| ONCBeOne Medicines Ltd. American Depositary Shares | $40.4B | — |
| ALNYAlnylam Pharmaceuticals Inc | $31.6B | — |
A dash means no fresh quote is cached for that symbol; this list does not fetch one.
Funds that hold AXSM
9 of the 239 funds whose filed holdings we currently hold own AXSM shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns AXSM.
Shariah funds| Fund | AXSM in fund | Fund compliant by weight |
|---|---|---|
| MNZL Manzil Russell Halal USA Broad Market ETF | 0.03% | 88% |
Widely held U.S. index funds. If you own one, you own AXSM through it. None of them is a Shariah fund; the last column is our look-through of each.
| Fund | AXSM in fund | Fund compliant by weight |
|---|---|---|
| IWF iShares Russell 1000 Growth ETF | 0.03% | 69% |
| VTI VANGUARD TOTAL STOCK MARKET INDEX FUND | 0.01% | 54% |
| ITOT iShares Core S&P Total U.S. Stock Market ETF | 0.01% | 54% |
| SCHB Schwab U.S. Broad Market ETF | 0.01% | 53% |
| Fund | AXSM in fund | Fund compliant by weight |
|---|---|---|
| LFSC F/m Emerald Life Sciences Innovation ETF | 3.05% | 46% |
| TMSL T. Rowe Price Small-Mid Cap ETF | 0.31% | 43% |
| JHMM John Hancock Multifactor Mid Cap ETF | 0.07% | 47% |
| TEIHX Nuveen Equity Index Fund | 0.01% | 51% |
Sorted by AXSM’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names AXSM once, so a bond is not counted as the shares. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Israel Englander | Millennium Management | $266M | 0.1% | 2026-09-30 |
| David Shaw | D. E. Shaw & Co. | $125M | 0.1% | 2026-09-30 |
| Ken Griffin | Citadel Advisors | $55M | 0.0% | 2026-09-30 |
| Steven Cohen | Point72 Asset Management | $41M | 0.0% | 2026-09-30 |
| Peter Brown | Renaissance Technologies | $38M | 0.1% | 2026-09-30 |
| Ray Dalio | Bridgewater Associates | $23M | 0.1% | 2026-09-30 |
| Chuck Royce | Royce & Associates | $17M | 0.2% | 2026-09-30 |
| Jefferies | Jefferies Financial Group | $6M | 0.0% | 2026-09-30 |
| Torray Investment Partners | Torray Investment Partners | $3M | 0.4% | 2026-09-30 |
| Paul Tudor Jones | Tudor Investment Corp | $2M | 0.0% | 2026-09-30 |
| John Hussman | Hussman Strategic Advisors | $1M | 0.2% | 2026-09-30 |
| Joel Greenblatt | Gotham Asset Management | $1M | 0.0% | 2026-09-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 35.30 | NEUTRAL |
| Stochastic %K (14) | 39.17 | NEUTRAL |
| CCI (20) | -86.43 | NEUTRAL |
| Williams %R (14) | -60.83 | NEUTRAL |
| MACD (12,26,9) | 1.48 | BUY |
| ROC (10) | -2.12 | SELL |
| Momentum (10) | -2.91 | SELL |
| EMA (10) | 138.82 | SELL |
| SMA (10) | 137.94 | SELL |
| EMA (20) | 143.58 | SELL |
| SMA (20) | 140.54 | SELL |
| EMA (30) | 150.01 | SELL |
| SMA (30) | 147.48 | SELL |
| EMA (50) | 162.27 | SELL |
| SMA (50) | 167.09 | SELL |
| EMA (100) | 179.93 | SELL |
| SMA (100) | 194.78 | SELL |
| EMA (200) | 182.57 | SELL |
| SMA (200) | 196.29 | SELL |
About AXSM
Healthcare · Biotechnology
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.
Background via Yahoo Finance — informational, not part of the verdict.
Latest Signal — 2026-11-03
Stop 135.25 Now 134.00 Target 143.53
🟠 NOT YET
The main driver: lagging the market by 8.1%. More negatives than positives right now. The setup isn't ready — check back when the trend or RSI changes.
Scores: 1 bullish / 2 bearish
Good setup, solid confluence
SMC — Top Down
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BULLISH | 64 |
| ⏰ 4H | RANGING | 38 |
| 🕐 1H | BEARISH | 98 |
| ⏱ 15-Min | RANGING | 130 |
| ⏲ 5-Min | BEARISH | 234 |
Momentum & Volume
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
Peer Movement
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
Before you act on this
The questions worth asking about any verdict on this page, answered plainly.
Is this a fatwa?
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Why can the standards disagree?
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
How often is this re-screened?
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
Do I need to purify dividends?
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Compare with
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider Activity (90d)
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NEUTRAL 0 buys · 0 sells
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-11-10 · Asset managers net 914130 (-14454)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.